By Requiring Pre-Market Listing, US FDA Could ‘Just Say No’ To Some Dietary Supplements – NPA
Proposal “seems driven by a desire to allow FDA to ‘bar the door’ from listing anything that they wish to keep out that doesn’t meet their convenience,” NPA CEO Daniel Fabricant tells Senate HELP Committee.
You may also be interested in...
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.
Some stakeholders have supported mandatory listing but they join opponents questioning legislation also authorizing FDA to prohibit sales of products compliant with manufacturing and labeling regulations but deficient, incomplete or late with registration information required for the agency.
HELP Committee Chairwoman Patty Murray, and ranking member Richard Burr also include supplement registration requirement in discussion draft for reauthorizing FDA’s user fee programs for prescription, generic and biosimilar drugs and medical devices.